🇺🇸 FDA
Pipeline program

Lumasiran

ALN-GO1-005

Phase 3 small_molecule completed

Quick answer

Lumasiran for Primary Hyperoxaluria Type 1 is a Phase 3 program (small_molecule) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Alnylam Netherlands B.V.
Indication
Primary Hyperoxaluria Type 1
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials